{"id":144035,"date":"2021-09-13T18:12:14","date_gmt":"2021-09-13T10:12:14","guid":{"rendered":"http:\/\/www.namnewsnetwork.org\/?p=144035"},"modified":"2021-09-13T18:12:16","modified_gmt":"2021-09-13T10:12:16","slug":"cureapp-hypertension-therapeutics-app-clinical-trial-results-announced-at-esc-congress-2021-and-published-in-the-european-heart-journal-a-leading-cardiovascular-journal","status":"publish","type":"post","link":"http:\/\/namnewsnetwork.org\/?p=144035","title":{"rendered":"CureApp Hypertension Therapeutics App: Clinical Trial Results Announced at ESC Congress 2021 and Published in the European Heart Journal, a Leading Cardiovascular Journal"},"content":{"rendered":"\n<p><strong>TOKYO, Sept 13 (Bernama-BUSINESS WIRE) &#8212;\u00a0<\/strong>The results of a Japanese Phase III domestic multicenter randomized controlled trial of a digital therapeutic app for hypertension (DTx) jointly developed by CureApp, Inc. (CEO Kohta Satake; hereafter \u201cthe Company\u201d) and Jichi Medical University were presented by Professor Kazuomi Kario of Jichi University\u2019s Department of Cardiovascular Medicine at the European Society of Cardiology Congress held at the end of August 2021 (ESC Congress 2021 &#8211; The Digital Experience: Late Breaking Trials in Hypertension). The results of this trial were also published in the European Heart Journal, one of the world\u2019s leading journals on cardiovascular disease.<br><br><strong>Summary of the clinical trial<\/strong><\/p>\n\n\n\n<p>This clinical trial*<sup>1<\/sup>\u00a0ran from January 2020 to December 2020 evaluating the efficacy and safety of the therapeutic app for patients with essential hypertension. This trial was performed as a comparative study of two groups, a control group who received guidance on lifestyle changes based on the Guidelines for the Management of Hypertension 2019 (hereafter, the \u201cGuidelines\u201d)*<sup>2<\/sup>, and an intervention group who used this therapeutic app in addition to applying lifestyle changes in accordance with said Guidelines.<br><br><a href=\"http:\/\/mrem.bernama.com\/viewsm.php?idm=40978\">http:\/\/mrem.bernama.com\/viewsm.php?idm=40978<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TOKYO, Sept 13 (Bernama-BUSINESS WIRE) &#8212;\u00a0The results of a Japanese Phase III domestic multicenter randomized controlled trial of a digital therapeutic app for hypertension (DTx) jointly developed by CureApp, Inc. (CEO Kohta Satake; hereafter \u201cthe Company\u201d) and Jichi Medical University were presented by Professor Kazuomi Kario of Jichi University\u2019s Department of Cardiovascular Medicine at the [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[315],"tags":[],"_links":{"self":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/144035"}],"collection":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=144035"}],"version-history":[{"count":0,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/144035\/revisions"}],"wp:attachment":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=144035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=144035"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=144035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}